Titan Partners initiated coverage of Altimmune (ALT) with a Buy rating and $7 price target The Phase II data suggest pemvidutide has a “competitive profile,” the analyst tells investors in a research note. Titan views Altimmune as a high risk/high reward stock with potential to exceed the price target if pemvidutide shows strong Phase III data.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT: